论文部分内容阅读
目的探讨健择联合卡铂治疗65岁以上患者进展期非小细胞肺癌疗效及毒性反应。方法选择我院收治的确诊为非小细胞肺癌患者112例按≥65岁与否分为研究组和对照组,比较两组化疗效果及化疗后毒性反应。结果观察组经治疗后有效患者22例,有效率39.3%,对照组有效患者26例,有效率46.4%,两组比较无统计学意义(X2=0.58,P>0.05)。观察组出现骨髓抑制、胃肠道不良反应例数比对照组高(P<0.05)。结论健择联合卡铂对≥5岁患者和<65岁患者化疗效果并无显著差别,毒性作用有轻微差异,我们建议对年龄≥65岁老年进展期非小细胞肺癌患者可考虑采用健择联合卡铂方案治疗。
Objective To investigate the efficacy and toxicity of gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer over 65 years old. Methods One hundred and twelve patients diagnosed as NSCLC admitted to our hospital were divided into study group and control group according to age ≥65 years old. The response to chemotherapy and the toxicity after chemotherapy were compared between the two groups. Results In the observation group, 22 patients were effective after treatment, the effective rate was 39.3%. The effective rate was 46.4% in the control group. There was no significant difference between the two groups (χ2 = 0.58, P> 0.05). In the observation group, myelosuppression and gastrointestinal adverse reactions were higher than those in the control group (P <0.05). Conclusions The combination of gemcitabine and carboplatin in patients ≥5 years old and <65 years old chemotherapy effect was no significant difference in toxicity there are slight differences, we recommend for patients aged 65 years or older advanced non-small cell lung cancer patients may consider the use of gemcitabine Carboplatin treatment.